- Home
- PYN vs BCLI Comparison
PYN vs BCLI Comparison
Compare PYN & BCLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYN
- BCLI
- Stock Information
- Founded
- PYN 2002
- BCLI 2000
- Country
- PYN United States
- BCLI United States
- Employees
- PYN N/A
- BCLI N/A
- Industry
- PYN Investment Managers
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PYN Finance
- BCLI Health Care
- Exchange
- PYN Nasdaq
- BCLI Nasdaq
- Market Cap
- PYN 34.6M
- BCLI 25.0M
- IPO Year
- PYN N/A
- BCLI N/A
- Fundamental
- Price
- PYN $6.15
- BCLI $2.43
- Analyst Decision
- PYN
- BCLI Strong Buy
- Analyst Count
- PYN 0
- BCLI 1
- Target Price
- PYN N/A
- BCLI $30.00
- AVG Volume (30 Days)
- PYN 19.9K
- BCLI 77.4K
- Earning Date
- PYN 01-01-0001
- BCLI 11-12-2024
- Dividend Yield
- PYN 5.07%
- BCLI N/A
- EPS Growth
- PYN N/A
- BCLI N/A
- EPS
- PYN N/A
- BCLI N/A
- Revenue
- PYN N/A
- BCLI N/A
- Revenue This Year
- PYN N/A
- BCLI N/A
- Revenue Next Year
- PYN N/A
- BCLI N/A
- P/E Ratio
- PYN N/A
- BCLI N/A
- Revenue Growth
- PYN N/A
- BCLI N/A
- 52 Week Low
- PYN $4.84
- BCLI $1.95
- 52 Week High
- PYN $6.60
- BCLI $11.85
- Technical
- Relative Strength Index (RSI)
- PYN 44.79
- BCLI 36.93
- Support Level
- PYN $6.09
- BCLI $1.97
- Resistance Level
- PYN $6.26
- BCLI $2.24
- Average True Range (ATR)
- PYN 0.06
- BCLI 0.37
- MACD
- PYN -0.02
- BCLI 0.03
- Stochastic Oscillator
- PYN 24.00
- BCLI 26.26
About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest
PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.